Healthcare >> Sector Roundtables >> December 18, 2000
RACHEL LEHENY, PhD, is a Senior Vice President at Lehman Brothers
covering Biotechnology. She was previously associated with Warburg
Dillon Read and Hambrecht & Quist. Prior to that Ms. Leheny was a
National Institutes of Health Fellow and a Lecturer in the Chemistry
Department at the University of California and also worked for Allen &
Company. She received an AB in Chemistry from Harvard College and a PhD
in Chemistry from Columbia University. Profile
MARK E. AUGUSTINE is a Senior Research Analyst with U.S. Bancorp Piper
Jaffray's Equity Research Group, where he focuses on biotechnology
companies. He was most recently a Biotechnology Analyst and a Vice
President in the Equity Research Department at SG Cowen Securities. He
previously worked at Morgan Stanley & Co. and Canaan Partners, a venture
capital firm. Mr. Augustine graduated Magna Cum Laude from Yale College
and received his MBA from Harvard University. Profile
JEFFREY W. CASDIN is a Chief Executive Officer, Principal at Cooper Hill
Partners, LLC, covering the biotechnology industry. He was previously
associated with Merrill Lynch and Oppenheimer & Company, Inc. He
received a ScB in Electrical Engineering, an AB degree from Brown
University and an MBA with High Distinction from Harvard University
Graduate School of Business where he was a Baker Scholar. Mr. Casdin is
a member of the Board of the National Genome Resource Center in Santa
Fe, New Mexico and he is also the Publisher of Biotech Investor, an
investment newsletter. Profile
you begin by telling us how you see the fundamentals underlying the
biotechnology industry today? How has the picture changed
